Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF Revaccination in Immunocompromised Adults
NCT07768345Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started Aug 2026; status: recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07768345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768345.